Crinetics Pharmaceuticals (CRNX) Misses Q3 EPS by 14c

Crinetics Pharmaceuticals (NASDAQ: CRNX) reported Q3 EPS of ($1.01), $0.14 worse than the analyst estimate of ($0.87). Revenue for the quarter came in at $350 thousand versus the consensus estimate of $123.5 thousand.

For earnings history and earnings-related data on Crinetics Pharmaceuticals (CRNX) click here.

You May Also Be Interested In

• TPU-As-A-Service could boost Google’s 2028 profit by over 15%: Barclays
• HSBC starts SpaceX at Hold, sees execution risks tempering long-term AI ambitions
• Canadian National Railway (CNI) Tops Q2 EPS by 15c